Joan Valls Marsal

Researcher

Joan Valls Marsal

Joan Valls Marsal holds a degree in Statistics (Polytechnic University of Catalonia-UPC, 2001), a Master of Public Health (Autonomous University of Barcelona, 2005) and a PhD in Medicine (University of Barcelona-UB, 2010).

After 3 years of experience as a statistician in the Consulting Service of the Autonomous University of Barcelona, in 2004 he joined the Catalan Institute of Oncology where he conducted his PhD studies focused on statistical methods for modelling mortality rates over time in breast cancer. In 2011 he moved to the Biomedical Research Institute of Lleida where he was the director of the Unit of Biostatistics and Epidemiology and participated in several research projects in the biomedical field. In 2021, he joined the International Agency of Research on Cancer (IARC) as Visiting Scientist, where he has been involved in several epidemiological analyses to assess HPV-based strategies for cervical cancer screening in low-income and middle-income countries. During this stay, he worked in ESTAMPA (EStudio multicéntrico de TAMizaje y triaje de cáncer de cuello uterino con pruebas del virus del PApiloma humano; Spanish acronym), a multicentric cross-sectional screening study including more than 40,000 women across 9 countries in Latin America, particularly assessing the performance of colposcopy for the triage of HPV-positive women.

More recently, in 2022 he has joined the Unit of Infections and Cancer – Information and Interventions (UNIC-I) in the Cancer Epidemiology Research Program (CERP) at the Catalan Institute of Oncology where he works in different research projects in the context of the global epidemiology of human papillomavirus (HPV) and related cancers. Particularly, he is involved in (1) PERCH (PartnERship to Contrast HPV), a Joint Action funded by the European Union with the aim of improving the coverage of HPV vaccine across Europe and (2) HPV-PI (HPV Protection Index), a research project with the aim of developing a new single measure that ranks countries and territories based on their cervical cancer prevention efforts by compiling and summarizing the most recent data worldwide on HPV vaccination coverage, cervical screening programs and cervical pre-cancer and cancer treatment at the country/regional level. This new tool, HPV-PI, has the goal of facilitating tracking progress towards cervical cancer elimination and supporting decision-making in government’s HPV prevention and control policies in the context of the three WHO targets (vaccination, screening and treatment) for cervical cancer elimination.

Email: jvalls@idibell.cat


SELECTED PUBLICATIONS:

Basiletti J, Valls J, Poklépovich T et al. Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections. PLoS One. 2022 Nov 23;17(11):e0278117. doi: 10.1371/journal.pone.0278117

Correa RM, Baena A, Valls J Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS One. 2022 Jul 29;17(7):e0272205. doi: 10.1371/journal.pone.0272205

Sancho-Saldaña A, Gil A, Quiranr-Sanchez B, (…), Valls J et al. Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies. J Clin Med. 2022 Apr 29;11(9):2509. doi: 10.3390/jcm11092509

Tebé C, Valls J, Satorra P, Tobías A. COVID19-world: a shiny application to perform comprehensive country-specific data visualization for SARS-CoV-2 epidemic. BMC Med Res Methodol. 2020 Sep 21;20(1):235. doi: 10.1186/s12874-020-01121-9

Valls J, Cambray S, Pérez-Guallar C et al. Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort. Front Genet. 2019 Feb 26;10:118. doi: 10.3389/fgene.2019.00118

Valls J, Baena A, Venegas et al. Performance of standardized colposcopy to detect cervical precancer and cancer for triage of HPV-positive women participating in ESTAMPA, a multicentric cross-sectional screening study. The Lancet Globat Health (ACCEPTED)

Baena A, Mesher D, Salgado Y,(…), Valls J, et al. Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study. Int J Cancer. 2022. (IN PRESS)

Rol ML, Picconi MA, Ferrera A,(…), Valls J, et al. Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study. Front Med (Lausanne). 2022 Nov 17;9:1006038. (IN PRESS)